Vimta Labs (524394) Q1 26/27 earnings summary

Executive summary

• Total income for Q1 FY 2027 reached INR 1,129 million, up 13.7% year-on-year, with stable sequential revenues despite mixed demand in some services.

• EBITDA reached INR 411 million with a margin of 36.4%, and PAT stood at INR 210 million with an 18.6% margin.

• EPS for the quarter was INR 4.71, up from INR 4.25 in Q1 FY26.

• Clinical research operations began recovering after prior challenges, with healthy inquiry and order inflows.

• The environment division was integrated with the food division for operational efficiency; food testing saw a decline in import/export samples due to global challenges, but domestic focus helped mitigate impact.

Financial highlights

• Revenue from operations for Q1 FY27 was INR 1,091 million, up 11.8% year-on-year.

• EBITDA margin remained strong at 36.4%, slightly down from 37.6% in the previous quarter.

• PAT margin was 18.6%, consistent with prior quarters.

• Net profit for the quarter was INR 210.42 million, up from INR 188.94 million in the same quarter last year.

• Basic EPS for the quarter was INR 4.71, compared to INR 4.25 in Q1 FY26.

Outlook and guidance

• Management remains confident in maintaining growth momentum, targeting 20%-25% annual growth, barring global disruptions.

• Plans to penetrate new markets and invest in service innovations and technology.

• Margins expected to remain stable or improve as business grows.

• Biologics segment expected to contribute significantly to top line and margin from the third year onward.

• 40,500 employee stock options were granted under the ESOP 2021 plan during the Board meeting on July 20, 2026.